

Varicella Zoster Infection Followed by Steroid Use: A Case Report

Sneha Merin John^{1*}, Christy Mary Sam² and Jobin Koshy¹

¹Department of Pharmacy, Dr. Joseph Marthoma Institute of Pharmaceutical Sciences and Research, Kerala, India

²Department of Pharmacy, School of Pharmacy, University of Nizwa, Birkat Al Mawz, Oman

Abstract

Varicella Zoster Virus (VZV) is a human virus that belongs to the herpes virus family. VZV is present worldwide and is highly infectious. We discussed a case report of 11-year-old female who is reported to have severe pain along the spine with abdominal pain and skin rashes. Her medical history reveals that she was discharged from the hospital with prednisolone. She returned back on the fifth day after discharge with the presenting complaints. It was observed that her hemoglobin level and platelet counts were decreasing. Even after starting treatment for her condition, she died at the fourth day. The case report underlines the development of immunosuppression in patients taking corticosteroids.

Keywords: Varicella zoster• Corticosteroids• Immunosuppression• Herpes virus• Platelet count

Abbreviations: VZV: Varicella Zoster Virus; TG: Trigeminal Ganglia; DRG: Dorsal Root Ganglia; HZ: Herpes Zoster; PHN: Postherpetic Neuralgia; Hcps: Health Care Professionals.

Introduction

Varicella-Zoster Virus (VZV) is a human alpha herpesvirus that infects >90% of people. Primary VZV infection, commonly seen during early childhood, leads to varicella (chickenpox) and establishment of a lifelong latent infection in neurons of Trigeminal Ganglia (TG) and Dorsal Root Ganglia (DRG). Later in life, VZV reactivates in approximately one third of infected individuals to cause Herpes Zoster (HZ shingles) [1]. Whereas primary VZV infection is generally benign, HZ is frequently accompanied by Postherpetic Neuralgia (PHN), and it is an important cause of uveitis and vasculitic stroke [2,3]. VZV is highly communicable and spreads by the airborne route, with an extraordinarily high transmission rate in temperate countries [4]. Varicella-Zoster Virus (VZV) causes primary, latent, and recurrent infections. The primary infection is manifested as varicella (chicken pox) and results in establishment of a lifelong latent infection of sensory ganglion neurons. Prior to the introduction of vaccine in 1995, varicella was an almost universal communicable infection of childhood in the United States. Varicella is a more serious disease with higher rates of complications and deaths among infants, adults, and immunocompromised persons. Hospitalization rates for varicella are about 3-6 per 1,000 cases, and the complication rate ranges between 2% and 4%. Mortality rates are between 0 and 0.05 deaths/100,000 population per year in Europe [2]. Varicella-zoster virus infection reconfigures the T cells to become activated memory T cells with enhanced skin-homing capacity and reduced immune functions [5]. Consequently, VZV-infected T cells transport the virus to skin and possibly ganglia during primary infection [6]. Detection of VZV-infected T cells in blood during acute infection, and observations in the SVV model support the role of T cells for interhost dissemination of the virus [7,8]. Although HZ patients may develop a low viremia [9], the analogous role of T cells in VZV reactivation has not been described. We report a case of previously healthy 11-year-old female child with varicella who developed hemorrhagic varicella zoster encephalitis associated with severe sepsis, pneumonia, severe hypoalbuminemia, and thrombocytopenia (Figure 1).




Figure 1. Varicella Zoster Virus.

Case Presentation

An 11-year-old South Indian female child weighing 30 kilograms was admitted to the hospital with severe pain along the spine for the last 8 hours, one episode of generalized tonic-clonic seizures, abdominal pain and skin rashes over the trunk.

Past medication history

Her past medication history revealed 30 days back she was hospitalized with the complaints of gradual and progressive joints swelling in the lower limbs, fever with rashes involving thigh, abdomen and face. She was diagnosed to have infection associated vasculitis with reactive arthritis and pneumonia. She was treated with acetaminophen p.o. 500 mg q.i.d. for 14 days, gentamycin i.v. 75 mg b.i.d. for 3 days, amikacin i.v. 220 mg b.i.d. for 11 days, ibuprofen p.o. 200 mg for 5 days, pethidene i.v. 15 mg t.i.d. for 6 days, cefotaxime i.v. 2 gm t.i.d. for 7 days, cloxacillin i.v. 1 gm q.i.d. for 10 days, naproxen p.o. 125 mg b.i.d. for 19 days, cloxacillin p.o. 750 mg q.i.d.

***Corresponding Author:** Sneha Merin John, Department of Pharmacy, Dr. Joseph Marthoma Institute of Pharmaceutical Sciences and Research, Kerala, India, Tel: +0479 233 9750; E-mail: snehamerinjohn1@gmail.com

Copyright: © 2020 John SM, et al. This is an open-access article distributed under the terms of the Creative Commons Attribution License, which permits unrestricted use, distribution, and reproduction in any medium, provided the original author and source are credited.

Received: September 24, 2020; Accepted: October 05, 2020 ; Published: October 12, 2020

for 5 days, ranitidine p.o. 75 mg b.i.d. for 12 days, prednisolone p.o. 60 mg in three divided doses for 8 days followed by 50 mg in three divided doses for 5 days. At the time of discharge, she was prescribed prednisolone p.o. 20 mg b.i.d. for 3 days, followed by 10 mg b.i.d. for 3 days and 10 mg o.d. for next 3 days, ranitidine p.o. 75 mg b.i.d. for 10 days and naproxen p.o. 125 mg b.i.d. for 7 days. She was on these medications for 4 days. On day 5 after discharge, she was readmitted to the hospital with the present complaints.

Physical examination

On examination pustular lesions filled with fluid were observed on trunk and abdomen. On abdominal examination tender hepatomegaly was present. Laboratory investigations at admission revealed positive-Tzank smear of pustular lesions, platelet counts-2.6 lakhs/mm³, Hemoglobin-13.1 gm/dl, total count-32,500 cells/mm³, INR-1.7, PT-20.1 sec(Control-12 sec), APTT-38.1 sec (Control-30 sec), D-dimer-10,000, ESR-18 mm/hr, serum creatinine 0.7 mg/dl. She was diagnosed to have hemorrhagic varicella zoster encephalitis.

Treatment

She was treated with acyclovir i.v. 300 mg q.i.d., pethidine i.v. 15 mg SOS, tramadol i.v. 25 mg q.i.d., naproxen p.o. 125 mg b.i.d., cefotaxime i.v. 125 mg q.i.d., gentamycin i.v. 75 mg b.i.d., phenytoin i.v. 150 mg b.i.d., mannitol i.v. 100 ml t.i.d., ranitidine i.v. 50 mg b.i.d., vitamin k i.v. 10 mg o.d. These medications were administered for 3 days. She was also transfused with 5 pints of platelets, 2 pints of packed cells and 40 ml of fresh frozen plasma. Laboratory investigations repeated on day 3 of admissions showed decrease in hemoglobin (5.5 g/dl), platelet count (30,000 cells/mm³), and increase in total count (68,100 cells/mm³), INR (4.4), PT-50.1 sec (control-12 sec), APTT-48.8 sec (control-30 secs), serum creatinine (1.6 mg/dl). She died on fourth day of hospitalization.

(Note: q.i.d: four times a day; b.i.d: two times a day; t.i.d: three times a day; iv: intravenous therapy; p.o: per os; od: oculus dexter).

Discussion

The VZV vaccine was approved by the US Food and Drug Administration in 1995 [10]. An association between steroid use and severe varicella has been recognized for decades, although most reports have come from relatively small retrospective series and case reports [11-14]. Glucocorticoids inhibit the formation of antibodies. The consequence of this interference with immune responses can be multiplication of bacteria and an increased risk of bacterial intoxication when infection does occur; hence, the frequency and severity of clinical infections tend to increase during glucocorticoid therapy. Infections such as chickenpox can have serious consequences, including death, in patients taking systemic glucocorticoids. It has been suggested that Varicella zoster immunoglobulin should be given to patients in contact with chickenpox if they have taken glucocorticoids in dosages over 0.5 mg/kg/day during the preceding 3 months, in the context of near-fatal chickenpox in a child receiving prednisolone. A similar incident was reported that a 12-year-old boy received a total of prednisone 4 mg and methylprednisolone 500 mg while in the hospital for treatment of an acute asthma attack. The patient was discharged on prednisone 10 mg/day and 3 days later developed a varicella rash. The immunosuppressive action of prednisone is believed to have allowed the infection to disseminate which eventually lead to the child's demise. In immunocompromised patients, such as in our case, acyclovir is recommended at the onset of varicella exanthem. Here, the patient is having back pain as the initial symptom. Use of corticosteroid increases the risk of severe or fatal varicella. Our patient was administered with high dose of steroid for 4 days. High dose of steroids (>2 mg/kg/day) seems to be dangerous than the low doses. The glucocorticoid effect of hydrocortisone 20 mg/kg/day is equivalent to prednisone 4 mg/kg/day. If corticosteroids were given at the incubation period of chicken pox the risk factors are high. It was reported that varicella is seen in patients taking intermittent course of high dose of corticosteroids.

Conclusion

The case report emphasizes the fact that immunosuppression occurs in a patient who is been administered with corticosteroids and it also highlights on the importance of starting acyclovir or similar antiviral on such group of patients at the onset of varicella infection. Health Care Professionals (HCPs) need to focus on these aspects while receiving patients who are on long-term or intermittent corticosteroids and need to provide adequate counseling to the patients who are on systemic corticosteroids.

References

1. Anne A, Gershon, Judith Breuer, Jeffrey I Cohen, and Randall J Cohrs, et al. "Varicella zoster virus infection." *Nat Rev Dis Primers* 1(2015):15016.
2. Donald H, Gilden, BK Kleinschmidt-DeMasters, James J LaGuardia, and Ravi Mahalingam, et al. "Neurologic complications of the reactivation of varicella-zoster virus." *N Engl J Med* 342(2000): 635-645.
3. Thomas J, Liesegang. "Herpes zoster ophthalmicus natural history, risk factors, clinical presentation, and morbidity." *Ophthalmology* 115(2008):S3-S12.
4. Anne A, Gershon. "Varicella zoster vaccines and their implications for development of HSV vaccines." *Virology* 435(2013): 915-958.
5. Nandini, Sen, Gourab Mukherjee, Adrish Sen and Sean C Bendall, et al. "Single-cell mass cytometry analysis of human tonsil T cell remodeling by varicella zoster virus." *Cell Rep* 8(2014): 633-645.
6. Werner, J D Ouwendijk, Ravi Mahalingam, Rik L de Swart, and Bart L Haagmans, et al. "T-cell tropism of simian varicella virus during primary infection." *PLoS Pathog* 9(2013): e1003368.
7. Yoshizo, Asano, Naoko Itakura, Yuji Kajita, and Sadao Suga, et al. "Severity of viremia and clinical findings in children with varicella." *J Infect Dis* 161(1990): 1095-1098.
8. Ozaki, Takao, Takayuki Ichikawa, Yoshiharu Matsui, and Hisashi Kondo, et al. "Lymphocyte-associated viremia in varicella." *J Med Virol* 19(1986):249-253.
9. Myron J Levin. "Varicella-zoster virus and virus DNA in the blood and oropharynx of people with latent or active varicella-zoster virus infections." *J Clin Virol* 61(2014):487-495.
10. Marietta, Vázquez. "Varicella zoster virus infections in children after the introduction of live attenuated varicella vaccine." *Curr Opin Pediatr* 16(2004): 80-84.
11. Scott F. Dowell and Joseph S. "Bresee severe varicella associated with steroid use." *Pediatrics* 92(1993): 223-228.
12. Gershon, A, Brunell PA, Doyle EF, and Claps AA. "Steroid therapy and varicella." *J Pediatr* 81(1972): 1034.
13. Kasper, William J, Howe Patricia "Fatal varicella after a single course of corticosteroids." *Pediatr Infect Dis J* 9(1990): 729732.
14. Robert J, Haggerty, and R Cannon Eley "Varicella and cortisone." *Pediatrics* 18(1956): 160-162.

How to cite this article: John, Sneha Merin, Christy Mary Sam and Jobin Koshy. "Varicella Zoster Infection Followed by Steroid Use: A Case Report." *Clin Schizophr Relat Psychoses* 14 (2020): 2. DOI:10.3371/CSRP.JSSC.101220